HIV感染女性上生殖道的免疫学、病毒学及药理学特征
Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.
作者信息
Rahangdale Lisa, De Paris Kristina, Kashuba Angela D M, Nelson Julie A E, Cottrell Mackenzie, Sykes Craig, Emerson Cindi, Young Steven L, Stevens Trenton, Patterson Kristine B, Cohen Myron S
机构信息
*Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC; †Center for AIDS Research, University of North Carolina, Chapel Hill, NC; ‡Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC; §Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; and ‖Health Sciences Center, University of Tennessee Health, Memphis, TN.
出版信息
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):420-4. doi: 10.1097/QAI.0000000000000480.
Abstract
: A comparative analysis of cellular and soluble markers of immune activation in HIV-infected women on combination antiretroviral therapy showed that the upper genital tract (UGT) compared to the lower female genital tract was characterized by higher frequencies of potential HIV target cells and increased inflammatory molecules. Despite the activated UGT milieu, HIV RNA could not be detected in paired samples of plasma, cervicovaginal or endometrial lavage. As antiretroviral concentrations were ≥3-fold higher in the endometrium than in the lower genital tract, high antiretroviral penetration and/or metabolism may limit viral replication in the UGT.
摘要
对接受联合抗逆转录病毒治疗的HIV感染女性的免疫激活细胞和可溶性标志物进行的比较分析表明，与女性下生殖道相比，上生殖道（UGT）的特征是潜在HIV靶细胞频率更高且炎症分子增加。尽管上生殖道环境处于激活状态，但在血浆、宫颈阴道或子宫内膜灌洗的配对样本中未检测到HIV RNA。由于子宫内膜中的抗逆转录病毒浓度比下生殖道高≥3倍，高抗逆转录病毒穿透率和/或代谢可能会限制上生殖道中的病毒复制。
相似文献
1
Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.HIV感染女性上生殖道的免疫学、病毒学及药理学特征
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):420-4. doi: 10.1097/QAI.0000000000000480.
2
Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy.接受有效联合抗逆转录病毒治疗的2型单纯疱疹病毒（HSV-2）/1型人类免疫缺陷病毒（HIV-1）合并感染女性的HSV-2生殖器排毒情况
Int J STD AIDS. 2016 Mar;27(3):178-85. doi: 10.1177/0956462415577727. Epub 2015 Mar 13.
3
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.高效抗逆转录病毒疗法对宫颈阴道HIV-1 RNA的影响。
AIDS. 2000 Mar 10;14(4):415-21. doi: 10.1097/00002030-200003100-00015.
4
Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections.女性生殖道炎症、HIV合并感染及持续性黏膜人乳头瘤病毒（HPV）感染
Virology. 2016 Jun;493:247-54. doi: 10.1016/j.virol.2016.03.022. Epub 2016 Apr 11.
5
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.女性生殖道中的抗逆转录病毒药物暴露：对口服暴露前和暴露后预防的影响。
AIDS. 2007 Sep 12;21(14):1899-907. doi: 10.1097/QAD.0b013e328270385a.
6
7
Longitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV-Infected and Uninfected Women.对感染和未感染HIV的女性进行全身和生殖道炎症标志物以及内源性生殖道大肠杆菌抑制活性的纵向评估。
Am J Reprod Immunol. 2016 Jun;75(6):631-42. doi: 10.1111/aji.12518. Epub 2016 May 5.
8
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies.宫颈阴道分泌物中HIV-1脱落的相关因素及抗逆转录病毒疗法的效果
AIDS. 2003 Oct 17;17(15):2169-76. doi: 10.1097/00002030-200310170-00004.
9
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.接受抗逆转录病毒治疗的1型人类免疫缺陷病毒感染女性生殖道中耐药变异株的选择。
J Infect Dis. 2000 Jul;182(1):112-22. doi: 10.1086/315679. Epub 2000 Jul 6.
10
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.两种替诺福韦制剂在男性生殖道中的细胞外分布不同，但细胞内分布相似。
Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.
引用本文的文献
1
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.替诺福韦、拉米夫定、依非韦伦和氟康唑在女性生殖组织中的渗透的死后分析。
J Antimicrob Chemother. 2022 Oct 28;77(11):3180-3186. doi: 10.1093/jac/dkac300.
2
Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.接受富马酸替诺福韦二吡呋酯/恩曲他滨治疗的年轻和老年HIV感染女性的细胞内替诺福韦和恩曲他滨浓度
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00177-20.
3
Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma.女性生殖道中 HIV-1 的脱落情况在血浆中 HIV-1 得到抑制的女性中较为罕见。
AIDS. 2020 Jan 1;34(1):39-46. doi: 10.1097/QAD.0000000000002373.
4
Mucosal Immunity in HIV/SIV Infection: T Cells, B Cells and Beyond.HIV/SIV感染中的黏膜免疫：T细胞、B细胞及其他方面
Curr Immunol Rev. 2019;15(1):63-75. doi: 10.2174/1573395514666180528081204.
5
Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.抗逆转录病毒药物在女性生殖道预防 HIV 感染中的药理学。
J Clin Pharmacol. 2018 Nov;58(11):1381-1395. doi: 10.1002/jcph.1270. Epub 2018 Jun 14.
6
Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.在感染HIV的男性和女性的肠道相关淋巴组织中，对拉替拉韦和多替拉韦的病毒学和免疫学反应。
Antivir Ther. 2018;23(6):495-504. doi: 10.3851/IMP3236.
7
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.激素避孕药对 TFV 和 TAF 抑制 HIV 感染和 TFV-DP 在血液和生殖道 CD4+T 细胞中的抑制作用存在差异。
Sci Rep. 2017 Dec 18;7(1):17697. doi: 10.1038/s41598-017-18078-3.
本文引用的文献
1
Phenotype and functionality of CD4+ and CD8+ T cells in the upper reproductive tract of healthy premenopausal women.健康绝经前妇女上生殖道中 CD4+ 和 CD8+ T 细胞的表型和功能。
Am J Reprod Immunol. 2014 Feb;71(2):95-108. doi: 10.1111/aji.12182. Epub 2013 Dec 6.
2
Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells.替诺福韦对 HIV-1 靶细胞中核苷酸酶和细胞因子的影响。
PLoS One. 2013 Oct 25;8(10):e78814. doi: 10.1371/journal.pone.0078814. eCollection 2013.
3
HIV-DNA in the genital tract of women on long-term effective therapy is associated to residual viremia and previous AIDS-defining illnesses.长期有效治疗的女性生殖道中的 HIV-DNA 与残余病毒血症和先前的艾滋病定义性疾病相关。
PLoS One. 2013 Aug 21;8(8):e69686. doi: 10.1371/journal.pone.0069686. eCollection 2013.
4
Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.多替拉韦在HIV阴性女性生殖道中的单剂量和多剂量药代动力学。
Antivir Ther. 2013;18(8):1005-13. doi: 10.3851/IMP2665. Epub 2013 Jul 31.
5
Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.口服替诺福韦在血浆、外周血单核细胞、结肠组织和阴道组织中的单剂量药代动力学。
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50. doi: 10.1089/aid.2013.0044. Epub 2013 May 29.
6
Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle.人体宫颈组织体外培养的 HIV-1 感染具有生产能力，这与月经周期的分泌期有关。
Mucosal Immunol. 2013 Nov;6(6):1081-90. doi: 10.1038/mi.2013.2. Epub 2013 Feb 6.
7
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.MTN-001：比较替诺福韦阴道凝胶和口服片剂在阴道组织和其他部位的随机药代动力学交叉研究。
PLoS One. 2013;8(1):e55013. doi: 10.1371/journal.pone.0055013. Epub 2013 Jan 30.
8
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.HIV 感染绝经前女性生殖道中依非韦伦、阿扎那韦、拉米夫定和替诺福韦的药代动力学模型。
Clin Pharmacokinet. 2012 Dec;51(12):809-22. doi: 10.1007/s40262-012-0012-y.
9
Associations between genital tract infections, genital tract inflammation, and cervical cytobrush HIV-1 DNA in US versus Kenyan women.生殖道感染、生殖道炎症与美国和肯尼亚女性宫颈细胞刷 HIV-1 DNA 之间的关联。
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):143-8. doi: 10.1097/QAI.0b013e318274577d.
10
Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation.生殖器炎症可预测 HIV-1 脱落，与血浆病毒载量和全身炎症无关。
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):436-40. doi: 10.1097/QAI.0b013e31826c2edd.
Zotero 插件